AC Immune S.A.ACIUNASDAQ
Loading
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | -92.32% | +0.00% | +90.10% | -96.32% |
| Gross Profit Growth | +0.00% | -92.32% | +0.00% | +90.10% | -96.32% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | -355.86% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | -322.40% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | -388.17% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | -366.67% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | -420.00% |
| Weighted Average Shares Growth | +18.66% | +30.80% | +1.03% | +1.09% | -0.73% |
| Weighted Average Shares Diluted Growth | +19.87% | +19.87% | +1.03% | +1.09% | -1.73% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | -1937.50% | -121.36% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | -2574.58% | -121.89% | +0.00% |
| Receivables Growth | +8034.62% | -92.70% | +991.01% | +430.10% | -98.42% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +70.82% | +26.31% | +26.18% | -19.92% | -29.74% |
| Book Value per Share Growth | -12.70% | -46.57% | -35.15% | -40.09% | -51.67% |
| Debt Growth | +28.83% | +55.19% | +55.45% | +52.34% | +51.18% |
| R&D Expense Growth | +16.72% | +7.79% | +4.95% | -1.82% | -9.74% |
| SG&A Expenses Growth | +8.31% | +0.00% | -10.62% | -14.39% | -4.96% |